This FMT Protocol Gives Researchers Reliable, Drug-Free Colitis in Mice Every Time

Reproducing a disease reliably in a laboratory animal sounds straightforward, but inflammatory bowel disease researchers know it is anything but. IL-10-deficient mice are supposed to develop spontaneous colitis, yet disease onset in these animals is notoriously unpredictable, arriving at different times in different animals and often requiring anti-inflammatory-disrupting drugs to synchronize it. A new study published in Frontiers in Microbiology by Prabhdeep Kaur and Jesús Rivera-Nieves describes a standardized fecal microbiota transplantation (FMT) protocol that sidesteps all of that, triggering colitis in nearly 100 percent of recipient mice through microbiota alone, with no pharmacologic intervention required.

FMT from Colitic Donor Mice Triggers Consistent Colitis in Recipients

The core finding is that gut microbiota from a severely inflamed donor strain can reliably transfer disease to genetically susceptible recipients. Kaur and Rivera-Nieves used double-knockout (DKO) mice lacking both interleukin-10 and the integrin beta-7 subunit (Il10-/-; Itgb7-/-). These animals develop particularly severe colitis, impaired mucosal immune regulation, and reduced IgA responses, meaning their microbial communities are heavily skewed toward colitogenic species. When fecal slurry from these colitic DKO donors was gavaged into standard IL-10-deficient recipient mice aged 8 to 10 weeks, colitis emerged in virtually every animal. Clinical signs, including weight loss, loose stools, reduced activity, and in some cases rectal prolapse, typically appeared within 2 to 4 weeks of starting the transplants. Histological examination of colon tissue confirmed the picture: epithelial hyperplasia, mucosal ulceration, and dense inflammatory cell infiltration consistent with genuine colitis, not a transient irritation.

Why Cleaner Mouse Models of IBD Still Matter

The stakes here are primarily methodological, but the downstream implications are real. IL-10 and IL-10 receptor deficiencies are among the best-characterized links between immune homeostasis and gut inflammation, and mutations in these genes cause very early onset inflammatory bowel disease in human patients. Mouse models that faithfully replicate microbiota-driven colitis without exogenous chemical insults are the closest preclinical approximation of that biology. The problem with the dominant alternative, piroxicam acceleration, is that the drug triggers disease partly through epithelial barrier disruption, increased apoptosis, and enhanced bacterial translocation, mechanisms that are not necessarily central to the spontaneous colitis the researchers are trying to model. Other chemical approaches like DSS and TNBS carry similar confounds. A protocol that transfers colitis through gut bacteria alone keeps the mechanistic focus where IBD biology actually lives.

How the Protocol Standardizes a Notoriously Variable Process

The reproducibility breakthrough rests on several specific procedural choices that address known failure points in murine FMT research. Fecal pellets from colitic DKO donors older than 12 weeks were pooled across animals, rapidly processed on ice to preserve anaerobic bacteria, aliquoted, and stored at minus 80 degrees Celsius. Before each gavage, frozen aliquots were thawed, homogenized in sterile phosphate-buffered saline, and centrifuged, then resuspended to a standardized optical density of OD600 between 1.5 and 2.0. Recipient IL-10-deficient mice received 200 microliters of that slurry via oral gavage three times per week for nine consecutive weeks. Recipient animals were pre-screened to confirm they had no existing colitis before enrollment.

That density standardization step is worth pausing on. Inconsistent procedural details are a well-documented problem across murine FMT studies, and variable inoculum loads are one of the main reasons results fail to replicate across laboratories. Measuring optical density at 600 nm gives researchers a quantitative handle on bacterial concentration that weight-based or volume-based approaches do not. The GRAFT guidelines, developed specifically to address reproducibility gaps in preclinical FMT protocols, have flagged this kind of standardization as a priority for the field; the Kaur and Rivera-Nieves protocol operationalizes it.

Sample collection at study end was comprehensive: colon, cecum, Peyer's patches, mesenteric lymph nodes, cecal patch, serum, and fecal pellets were all harvested, enabling histopathology, flow cytometry, gene expression analysis, ELISA, and microbiome profiling in parallel.

Open Questions About Donor Variability and Cross-Facility Reproducibility

The authors are clear about what the protocol does not yet solve. Microbial composition differs between individual donors even within the DKO strain, and while pooling reduces that variability it does not eliminate it. Cage-specific microbiota and housing environment can independently shape disease severity, a limitation that affects every mouse IBD model and that germ-free and barrier-raised mouse approaches address only partially, at the cost of reduced microbial diversity. The study did not directly confirm microbial engraftment by sequencing recipient gut communities after FMT; disease transfer served as the readout instead. Researchers in facilities without access to the DKO donor strain will face a practical barrier to adoption. And because IL-10-deficient mice reflect a specific immune dysregulation, they capture some but not all aspects of the broader human IBD spectrum.

The precise microbial or functional features that make the DKO community so colitogenic remain undefined. Identifying those taxa or metabolic pathways is an obvious next step, one that could eventually allow researchers to engineer defined synthetic communities rather than relying on whole-fecal transfers.

A Cleaner Platform for Microbiome-Targeted IBD Therapies

The protocol's immediate practical value is as a screening platform. Because disease induction is now microbiota-driven and highly consistent, researchers can use it to test whether a given intervention, a probiotic, a prebiotic, a microbiome-modulating drug, or a novel FMT formulation, actually modifies the colitogenic microbial community or merely suppresses inflammation downstream. That distinction matters enormously for the field. FMT in IBD has produced variable clinical results, and one reason is that preclinical models have not reliably distinguished microbiome-dependent from microbiome-independent effects.

This is early-stage research. The model needs validation across independent laboratories and across different housing facilities before it can be considered a field standard. But the combination of a chemically clean induction mechanism, quantitative inoculum standardization, and near-complete disease penetrance addresses three longstanding criticisms of the IL-10-deficient mouse system simultaneously. For researchers trying to understand how specific gut bacteria drive chronic intestinal inflammation, that is a meaningful step forward.

Evidence rating

INVESTIGATIONAL — 61/100

Caveats:

• This is an animal study only — all findings are in genetically modified mice, not humans.
• Microbial engraftment was inferred from disease transfer and was not directly confirmed by sequencing.
• The specific microbial species or functional features responsible for colitogenicity have not been identified.
• Funding was not disclosed in the article.

Preclinical protocol study conducted entirely in genetically modified mice. Demonstrates consistent colitis induction via repeated FMT from double-knockout donors, but microbial engraftment was not confirmed by sequencing and the responsible microbial taxa remain undefined. No human data are presented, and findings await independent replication.

References

1. Prabhdeep Kaur, Jesús Rivera-Nieves (2026). A standardized fecal microbiota transplantation protocol enables consistent, microbiota-driven colitis in IL-10-deficient mice. Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2026.1842264
2. Jun Xiao, Ziqing Ye, Ying Huang (2026). A Comprehensive Review of IL-10 and IL-10 Receptor Deficiencies: From Basic Science to Clinical Bedside. Clinical Reviews in Allergy & Immunology. https://doi.org/10.1007/s12016-026-09154-6
3. Suresh C. Bokoliya, Yair Dorsett, Hunter Panier, Yanjiao Zhou (2021). Procedures for Fecal Microbiota Transplantation in Murine Microbiome Studies. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2021.711055
4. Kate R. Secombe, Ghanyah H. Al-Qadami, Courtney B. Subramaniam, et al. (2021). Guidelines for reporting on animal fecal transplantation (GRAFT) studies: recommendations from a systematic review of murine transplantation protocols. Gut Microbes. https://doi.org/10.1080/19490976.2021.1979878
5. Patricia V. Turner (2018). The role of the gut microbiota on animal model reproducibility. Animal Models and Experimental Medicine. https://doi.org/10.1002/ame2.12022
6. Fecal microbiota transplantation: current challenges and future landscapes. NIH. https://pubmed.ncbi.nlm.nih.gov/38870195/